The effect of modulating the synthesis of XXXX cascade products on @entity75 recurrence.

@entity3217 @entity5728 @entity75 @entity19 @entity2605 @entity1426 @entity2644 @entity134 @entity272 @entity230 @entity130
Induction of @entity75 recurrence may be achieved by a variety of stimuli. @entity130 of almost any kind (physical, chemical, electromagnetic and thermal) to the healed primary lesion site has been successful for induction of recurrence. In common with each of these mechanisms is the release of inflammatory mediators ( @entity1426 (AA), complement, kinins, etc.) following @entity130 . Because blockade of the AA cascade with @entity230 has been noted to @entity272 , and because @entity230 have numerous side effects making them a poor therapeutic choice in @entity3217 , we decided to test several relatively different types of AA cascade inhibitory drugs in @entity19 ear HSV recurrence models. In this series of experiments, it was found that topical @entity230 gave the greatest initial decrease in lesion number (80% fewer than control on day 3 post recurrence induction (PRI), while @entity5728 resulted in the greatest reduction of lesions by day 5 PRI (85% fewer lesions than control and 60% fewer than the @entity134 treated group). The @entity2605 treated group exhibited the least reduction in recurrence severity (27% fewer lesions than control on day 5 PRI and 200% more lesions than the @entity134 group. @entity2644 ( @entity2644 ) acted roughly equivalent to the @entity134 treated group by day 5 PRI (70% fewer lesions than the untreated control group). Relative efficacy in lesion reduction between groups by day 5 PRI is: @entity5728 greater than @entity134 = @entity2644 greater than NDGA greater than control. @entity5728 , @entity134 and @entity2644 significantly reduced lesions (p less than .05) when compared with the saline treated control @entity19 . NDGA did not significantly reduce lesions by day 5 PRI.
